News
-
So many shareholders have already voted against Elan’s proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan… Read more . . .
-
OINDP device maker Aptar Pharma has added Chinese, French, German and Spanish versions to its English-language website and plans to add additional languages, including Portuguese, in 2014. According to the company, web traffic has grown… Read more . . .
-
AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if… Read more . . .
-
Hovione has announced the appointment of Justin Hughey, who was most recently Director of Research for Enavail to head its US Particle Design sciences at our site in New Jersey. The company says that it… Read more . . .
-
Finnish drug developer Biotie Therapies has announced that it is paying $1 million for an exclusive option to acquire Neurelis, Inc., which is developing NRL-1, an intranasal diazepam formulation for the treatment of epilepsy. The… Read more . . .
-
Jolyon Mitchell has long been a leading voice in OINDP development and analysis through numerous publications and through service to multiple organizations . . . Read more Read more . . .
-
Device manufacturer Rexam Healthcare has announced a €20 million expansion of its manufacturing operations at its site in Le Tréport, France, giving the site a total workspace of 5200 sq m. Rexam will manufacture the… Read more . . .
-
Israeli device company Inspiro Medical has announced that a safety and efficacy study of formoterol delivered by the Inspiromatic dry powder inhaler for the treatment of asthma in children met both its primary and secondary… Read more . . .
-
Meda has announced an expansion in its partnership with Cipla, which is already supplying azelastine for Meda’s Dymista nasal spray. With the new agreement, Meda will continue to take responsibility for clinical development and commercialization… Read more . . .
-
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company’s GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.